Feed/Companies/Slate Medicines

Slate Medicines

As of 14 Oct 2026, Slate Medicines has raised $130M across 1 verified round on record; latest: $130 million Series A led by Forbion, Foresite Capital and 1 other, announced 24 Feb 2026.

BUILT ON

Visit site

Next-generation therapeutics for migraine and headache disorders targeting pathways involved in migraine pathophysiology.

slatemedicines.comLinkedInBiotech

LATEST ROUND

Series A

$130M · 2026-02-24

RAISED ON RECORD · USD

$130M

across 1 verified round

INVESTORS

3 leads

SOURCES

from 1 publisher

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Series A

$130M · 2026-02-24

[ HISTORY ]

led by Forbion, Foresite Capital, RA Capital Management

Round	Amount	Announced	Lead	Buzz
Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$130M	2026-02-24	Forbion, Foresite Capital, RA Capital Management	No recent discussion
1 source [ VERIFIED ] read against 1 source The release's Raleigh, N.C. dateline does not establish the company's headquarters.

Slate Medicines

Company

Rounds

Sources

Profile

Investors

Slate Medicines

Rounds

Profile

Sources

Series A$130M2026-02-241 source

Investors

Series A$130M2026-02-243 investors